New Delhi, May 29 (H.S.): Q-Line Biotech delivered a strong stock market debut on Thursday, rewarding its IPO investors with significant gains. The healthcare company, which manufactures diagnostic equipment, made an impressive entry into the equity markets.

The company’s initial public offering (IPO) shares were issued at ₹343 per share. On listing day, the stock debuted on the NSE SME platform at ₹452, reflecting a 32 percent premium over the issue price. Trading began shortly after the strong listing.

Soon after listing, the stock witnessed profit-booking, pulling it down to an intraday low of ₹431. However, renewed buying interest pushed the shares higher again, eventually hitting the upper circuit limit of ₹474.60, where it also closed for the day.

This resulted in IPO investors earning a profit of ₹131.60 per share on the first trading day itself, translating into a gain of 38.37 percent.

The ₹214.48 crore IPO opened for subscription between May 21 and May 25 and received an overwhelming response from investors, being subscribed 102.42 times overall. The Qualified Institutional Buyers (QIB) portion was subscribed 123.94 times, while the Non-Institutional Investors (NII) segment saw a subscription of 145.98 times. The retail investor quota was subscribed 71.44 times.

The IPO consisted of 62,53,200 fresh equity shares with a face value of ₹10 each. The funds raised through the issue will be used for debt repayment, working capital requirements, and general corporate purposes.

According to documents filed with SEBI in the Draft Red Herring Prospectus (DRHP), the company’s financial performance has shown fluctuations but remained broadly strong. Net profit stood at ₹32.10 crore in FY 2022–23, increased to ₹34.44 crore in FY 2023–24, and then declined to ₹28.13 crore in FY 2024–25. However, during April–December FY 2025–26, the company reported a net profit of ₹38.69 crore.

Revenue continued to grow steadily over the years. It rose from ₹184.81 crore in FY 2022–23 to ₹206.45 crore in FY 2023–24, and further surged to ₹322.58 crore in FY 2024–25. During April–December FY 2025–26, revenue stood at ₹236.50 crore.

The company’s debt also increased consistently over the period. Total borrowings stood at ₹73.65 crore in FY 2022–23, rose to ₹96.91 crore in FY 2023–24, and jumped to ₹164.95 crore in FY 2024–25. By April–December FY 2025–26, debt had climbed further to ₹243.85 crore.

Reserves and surplus also showed steady growth, increasing from ₹125.79 crore in FY 2022–23 to ₹160.24 crore in FY 2023–24, and further to ₹188.37 crore in FY 2024–25. During April–December FY 2025–26, it rose to ₹212.89 crore.

EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortisation) stood at ₹32.98 crore in FY 2022–23, increased to ₹37.63 crore in FY 2023–24, and surged to ₹71.32 crore in FY 2024–25. In April–December FY 2025–26, EBITDA stood at ₹64.23 crore.

---------------

Hindusthan Samachar / Jun Sarkar